The company's software-related revenues grew year over year, but its sequencing and molecular analysis revenues declined.
The research-use-only system, which has a list price of $299,000, fits with Thermo Fisher's vision of a future of disseminated implementation of NGS.
The firms will codevelop companion diagnostics for anti-PD1/PD-L1 immunotherapy treatments for cancer.
FIND also announced support for projects from Axxin and DNC Dx for point-of-care detection of sexually transmitted infections.
Hitachi and Centre Léon Bérard have opened a research lab in Lyon that will apply AI to medical imaging and predict response to radiation therapy from genomic markers.
The firm's diagnostics revenues decreased 9 percent to $33.4 million, and life sciences revenues increased 7 percent to $17.4 million.
The German company offers rare disease genetic tests and services for clinical applications, as well as to support drug discovery and development programs.
The firm generated $56.5 million in revenue compared to $37.4 million in Q3 2018, and beat the consensus Wall Street estimate of $55.0 million
The company processed more than 200,000 tests during the quarter, an increase of 20 percent compared to the 167,000 tests it processed in Q3 of last year.
The firm's diagnostics revenues also grew 6 percent year over year with molecular diagnostics revenues up 9 percent.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.
The firm said that ePlex revenues grew 98 percent compared to Q3 2018, and the firm placed 51 net new ePlex analyzers.
The company continues to move toward its planned merger with German diagnostics firm Curetis, which is expected to close early next year.
Invitae is providing the testing services as part of the 12-month pilot, while patients will have the option to share their results with researchers though LunaDNA.
The funding will be used in part to settle a convertible bond facility Novacyt entered into earlier this year, as well as for working capital.
Emerging from stealth mode, the Toronto-based firm will use the platform to identify circulating tumor cells and spur drug development in the lung cancer space.
Promega's microsatellite instability technology will be used to develop an on-label, solid tumor companion diagnostic for pembrolizumab.
The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
It is the first time that the agency has authorized for marketing a next-generation sequencing test for HIV-1 resistance, the FDA noted.
The University of California, Berkeley's Jennifer Doudna reflects at Science on the anniversary of the announcement of the birth of twin girls who underwent genome editing.
By studying its enamel proteome, researchers have found the ancient ape Gigantopithecus blacki belongs to a sister clade to that of orangutans.
Bloomberg Businessweek discusses genomics with BGI's Wang Jian.
In Science this week: researchers find transplanting the gut microbiome in mice affects physiology, and more.